In a nutshell This study investigated the effectiveness and safety of lenalidomide (Revlimid) plus everolimus (Afinitor) in pretreated patients with relapsed (recurrent) or refractory (does not respond to treatment) lymphoma. This study concluded that this combination was well-tolerated and showed promising effectiveness in these patients. Some...
Read More
In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with previously untreated, advanced stage (stage 3 – 4) follicular lymphoma (FL). This study concluded that this regimen was similarly effective as rituximab plus chemotherapy, but had different side effects. Some...
Read More
In a nutshell This study investigated the impact of older age on the outcomes of patients with non-Hodgkin’s lymphoma (NHL) who underwent allogeneic stem cell transplantation (alloSCT). This study concluded that alloSCT in patients older than 65 was associated with higher risks. Some background More than 60% of patients with NHL are older than...
Read More
In a nutshell This study looked at the evidence for the safety of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Researchers found that this drug is safe to use in these patients. Some background Leukemia and lymphoma are types of cancer of the bone marrow. They can lead to...
Read More
In a nutshell This study compared the effectiveness of mogamulizumab (Poteligeo) versus vorinostat (Zolinza) in patients with previously treated cutaneous (skin) T-cell lymphoma (CTCL). This study concluded that mogamulizumab was well-tolerated and significantly more effective than vorinostat in these patients. Some background CTCL is a rare type of...
Read More
In a nutshell This study evaluated the safety and effectiveness of ibritumomab tiuxetan (Zevalin) followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that ibritumomab tiuxetan...
Read More
In a nutshell This study compared the outcomes of radioimmunotherapy versus rituximab (Rituxan) maintenance therapy in patients with follicular lymphoma (FL). This study concluded that radioimmunotherapy shows similar survival outcomes compared to rituximab maintenance therapy in patients with FL. Some background In patients with FL, rituximab...
Read MoreIn a nutshell This study investigated the long-term outcomes of radioimmunotherapy following first-line (primary) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced-stage follicular lymphoma (FL). This study concluded that this treatment approach is effective and well-tolerated in...
Read More
In a nutshell This study evaluated the safety and effectiveness of lenalidomide (Revlimid) plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy in previously untreated patients with follicular lymphoma (FL) and a high tumor burden (a large number of cancer cells or tumors in the body). This study concluded that...
Read More
In a nutshell This study investigated the impact of watchful waiting on the outcomes of patients with follicular lymphoma (FL). This study concluded that these patients had a higher risk of disease transformation compared to patients who receive immediate treatment. Some background About 15 – 30% of patients with FL have advanced-stage (stage 3...
Read More
In a nutshell This article provided recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL). Some background Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL). It accounts for about 30% of new NHL cases in the U.S. Current treatments are effective in 60 – 70% of patients....
Read More
In a nutshell This study evaluated the effectiveness and safety of the BendaEAM (bendamustine, etoposide, cytarabine, melphalan) in patients with lymphoma undergoing autologous stem cell transplantation (auto-SCT). This study concluded that BendaEAM is a feasible option for these patients, with minimal side effects. Some background High-dose...
Read More
